Metastatic Colorectal Cancer Immunotherapy with GUCY2C-Expressing Listeria monocytogenes
Abstract
This objective of this project is to define the ability of a new vaccine to treat colorectal cancer in animal models. The vaccine uses attenuated Listeria monocytogenes to deliver GUCY2C, a colorectal cancer antigen to "antigen-presenting cells" (APCs) to induce GUCY2C-specific T cell responses against GUCY2C which may find and eliminate colorectal cancer. The project tests novel recombinant Listeria monocytogenes vaccines produced in our laboratory in mouse models of colorectal cancer to determine their activity, efficacy, and safety. If successful, the results of these studies could be applied to patients with metastatic colorectal cancer, a disease that is typically fatal.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2018
- Accession Number
- AD1062516
Entities
People
- Adam E. Snook
Organizations
- Thomas Jefferson University